Previous studies have demonstrated that lipophilic antifolates such as trimetrexate, which do not rely on polyglutamation for activation, exhibit potent efficacy against ALL cells with diminished FPGS expression, suggesting a promising therapeutic alternative for this subset of patients [25]. This evidence concerns the gene FPGS and acute lymphoblastic leukemia.